Alcohol-associated liver disease is now the most common indication for liver transplantation in the U.S.  With a persistent national shortage of donor livers to meet the demand of waiting candidates, transplant centers have an ethical imperative to select candidates with anticipated capacity to care for the new organ, including adherence to post-transplant immunosuppression and the absence of direct injury to the new organ.  With historic relapse rates to drinking of up to 40-50%, transplant psychiatrists and the addiction team have the challenge of diagnosing substance use disorders in transplant candidates, guiding a treatment plan for establishment of abstinence and relapse prevention skills, and determining when the potential candidates move into a moderate to low risk of relapse.  With rapid national increase in prevalence of cannabis product use for recreational and medicinal purposes, cross-addiction to cannabis and cannabis interaction with post-transplant immunosuppression pose additional challenges for the practice.

ATTENDANCE / CREDIT
Text the session code (provided only at the session) to 507-200-3010 within 48 hours of the live presentation to record attendance. All learners are encouraged to text attendance regardless of credit needs. This number is only used for receiving text messages related to tracking attendance. Additional tasks to obtain credit may be required based on the specific activity requirements and will be announced accordingly. Swiping your badge will not provide credit; that process is only applicable to meet GME requirements for Residents & Fellows.

TRANSCRIPT
Any credit or attendance awarded from this session will appear on your Transcript.

For disclosure information regarding Mayo Clinic School of Continuous Professional Development accreditation review committee member(s) and staff, please go here to review disclosures.